The Procter & Gamble Company (NYSE:PG) – Teva-P&G joint venture teams up with Australia’s Swisse Wellness

The Procter & Gamble Company (NYSE:PG) [Reuters] – Israel’s Teva Pharmaceutical Industries will join forces with Australian vitamins, minerals, and supplements (VMS) company Swisse Wellness through Teva’s joint venture with Procter & Gamble Co, PGT Healthcare. PGT Healthcare will partner with Swisse Wellness to begin expanding its range of more than 100 vitamins, minerals and supplements globally over the next few years, the companies said on Tuesday. The licensing deal will integrate the companies’ strengths to enable the rapid expansion of the Swisse brand of VMS products to new countries. The collaboration will benefit from PGT Healthcare’s consumer understanding, marketing scale, and global regulatory expertise with Swisse Wellness’s VMS product development expertise, portfolio of more than 100 products, and unique marketing model.
Read more on this.

The Procter & Gamble Company (PG), valued at $229.47B, started the session at $84.31.
Looking at today’s trading action, the company’s one day range from $84.22 to $84.59 and has traded between $66.83 and $84.94 over the past 12 months.
 
Priced at 19.82x this year’s forecasted earnings, PG shares are relatively inexpensive compared to the industry’s 27.69x forward p/e ratio.
And for those looking to make a return holding the stock, the company pays shareholders $2.41 per share annually in dividends, yielding 2.80%.
 
In a review of the consensus earnings estimate this quarter, 21 sell-side analysts are looking at $1.21 per share, which would be $0.01 worse than the year-ago quarter and a $0.02 sequential decrease. Investors should also note that the full-year EPS estimate of $4.28 is a $0.23 improvement when compared to the previous year’s annual results.
 
The quarterly earnings estimate is based on a consensus revenue forecast of the current quarter of $22.37 Billion. If realized, that would be a 0.86% increase over the year-ago quarter.
In terms of ratings, Standpoint Research downgraded PG from Hold to Sell (May 24, 2013). Previously, UBS upgraded PG from Neutral to Buy.
Investors should keep in mind is that the average price target is $86.67, which is 2.80% above where the stock opened this morning.
 
The Procter & Gamble Company (NYSE:PG), together with its subsidiaries, manufactures and sells branded consumer packaged goods. The company operates through five segments: Beauty, Grooming, Health Care, Fabric Care and Home Care and Baby Care and Family Care.
 
Tag Helper ~ Stock Code: PG | Common Company name: Procter & Gamble | Full Company name: The Procter & Gamble Company (NYSE:PG) .

More on this topic (What's this?)
Procter & Gamble (PG) Dividend Stock Analysis 2014
Intra-day Bounce Levels For Procter & Gamble
Read more on Procter & Gamble Company at Wikinvest

Sharing the News


facebooktwittergoogle_plusredditlinkedinmail

Follow us for the Latest news


facebooktwittergoogle_pluslinkedinrss

NYSE, NASDAQ, Market Data, Earnings Estimates, Analyst Ratings and Key Statistics provided via Yahoo Finance, unless otherwise specified. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Jutia Group will not be liable for any errors, incompleteness or delays, or for any actions taken in reliance on the data displayed herein.

Related Articles


Comments are closed.